In a first, Huntington’s disease is slowed by an experimental treatment
SMRTR summary
An experimental gene therapy delivered directly to the brain has slowed Huntington's disease progression by up to 75 percent over three years in a small clinical trial of 17 patients. The treatment uses virus-delivered microRNA to reprogram brain cells to stop producing the toxic huntingtin protein that causes the fatal disease.
SMRTR provides this summary for quick context. The original article belongs to Science News.
Read the original article